FDA approves Elusys' Anthim for inhalational anthrax

FDA approved Anthim obiltoxaximab from Elusys Therapeutics Inc.

Read the full 82 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE